Compare Neurocrine Biosciences Inc (NBIX) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Warner Music Group Corp — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Warner Music Group Corp trades at $28.2 (market cap $14.64B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Warner Music Group Corp pays a 2.71% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | WMG | |
|---|---|---|
Market Cap | $17.40B | $14.64B |
Sector | Health | Media |
52-Week High | $180.55 | $34.72 |
52-Week Low | $123.10 | $23.65 |
Enterprise Value | $16.49B | $18.84B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Warner Music Group (WMG) trades at $27.945, down 1.36% on the day, amid a bearish technical signal. The stock shows mixed earnings performance, with a Q1 2026 beat but recent quarterly misses. Revenue growth is steady, reaching $6.71B in 2025, though net income margin has compressed to 5.44%. Recent strategic moves include a licensing renewal with NetEase Cloud Music and the acquisition of AI startup Sureel AI, positioning the company for growth in digital and AI-driven music markets.
WMG presents a compelling long-term opportunity with analyst consensus pointing to significant upside (target $41.00), supported by 66.66% buy ratings. However, risks include competitive pressures in streaming, margin volatility, and execution challenges in integrating AI technologies. The stock's current valuation multiples (P/E 33.4) suggest premium pricing relative to earnings, requiring sustained growth to justify investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
